Model DetailsLiver carcinoma
Model Name |
Liver carcinoma | Strain |
CD-1 |
Tumor Inducing Agent(s) |
Chemical/Drug : 3'-azido-3'-deoxythymidine (AZT) |
Tumor Synonym |
liver carcinoma |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Liver | Male |
4.3% (1 of 23 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
21.1% (4 of 19 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
37.5% (3 of 8 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
25.9% (7 of 27 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
16% (8 of 50 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
25% (2 of 8 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
4.2% (1 of 24 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
27.3% (6 of 22 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
16.7% (1 of 6 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
25% (7 of 28 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Male |
15.4% (8 of 52 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
25% (2 of 8 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
0% (0 of 22 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
7.7% (1 of 13 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
5.3% (1 of 19 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
6.25% (2 of 32 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
3.7% (2 of 54 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
0% (0 of 24 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
5.9% (1 of 17 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
10% (1 of 10 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
7.4% (2 of 27 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Liver | Female |
3.9% (2 of 51 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |